Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01052662 · ClinicalTrials.gov registry record · Phase 2
Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
A Phase 2 study of Opioid Dependence, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT01052662: Completed Phase 2 study of Opioid Dependence, sponsored by University of Massachusetts, Worcester.
NCT01052662 is a Phase 2 study of Opioid Dependence that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 87 participants, below the 155-participant average among 29 other Opioid Dependence trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01052662, a Phase 2 study of Opioid Dependence, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effect of memantine and buprenorphine on opioid abusing behavior, to determine the effect of memantine and buprenorphine on early relapse and to evaluate the tolerability of memantine co-administrated with buprenorphine. The study seeks to determine if combined treatment of memantine and buprenorphine may provide shorter-term treatment for opioid dependence.
Primary Outcome
The primary outcome variable was the change from baseline of the mean proportion of weekly opioid use assessed by self-reported days of use and/or positive urine drug screen during the previous week using the time-line followed-back method (TLFB) . A positive urine counted as 1, as did each self-reported day of use. Each participants total was divided by 8. Mean proportion by group were calculated by averaging the proportions across participants in that group.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Memantine
Study Locations (1)
Massachusetts
- University of Massachusetts Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
What the finished NCT01052662 record still lists
NCT01052662 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 155-participant average among 29 other Opioid Dependence trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Opioid Dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01052662 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01052662 about?
NCT01052662 is a clinical study titled "Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults". The purpose of this study is to examine the effect of memantine and buprenorphine on opioid abusing behavior, to determine the effect of memantine and buprenorphine on early relapse and to evaluate the tolerability of memantine co-administrated with buprenorphine. The study seeks to determine if com...
What is the current status of trial NCT01052662?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2009-10. Estimated completion is 2013-10.
What conditions does trial NCT01052662 study?
This clinical trial studies the following conditions: Opioid Dependence.
What interventions are being tested in trial NCT01052662?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT01052662?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01052662 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01052662's enrollment target sits among peer trials
87 17th of 29 higher than 13 of 29 other Opioid Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure
ACTIVE NOT RECRUITING · Phase 2
-
Treatment for Opioid Dependent Offenders
COMPLETED · Phase 2
-
Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
COMPLETED · Phase 2
-
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
COMPLETED · Phase 2
-
Neuromodulation and Cognitive Training in Opioid Use Disorder
RECRUITING · NA
-
Intervening With Opioid-Dependent MothersMothers and Infants
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia